Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-de... Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. Mehr anzeigen
Preclinical study anticipated to be published in 1H 2025 documenting combination’s additive and/or synergistic anti-inflammatory signal; Company will seek to advance asset in neurodegenerative...
This open-label Phase 1 study measures safety, peripheral and central inflammation, effects on Treg cell populations, and FTD progression; Five of the 8 planned FTD subjects have been enrolled to...
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.13 | 2.30088495575 | 5.65 | 5.99 | 5.51 | 28198 | 5.85414538 | CS |
| 4 | -0.0557 | -0.954469900783 | 5.8357 | 6.49 | 5.32 | 53443 | 5.81819849 | CS |
| 12 | -0.97 | -14.3703703704 | 6.75 | 7.55 | 5.1 | 62568 | 6.10809347 | CS |
| 26 | -1.67 | -22.4161073826 | 7.45 | 10.24 | 4.75 | 68282 | 6.77288046 | CS |
| 52 | -0.44 | -7.07395498392 | 6.22 | 10.6899 | 4.75 | 70976 | 7.66768902 | CS |
| 156 | 1.03 | 21.6842105263 | 4.75 | 10.6899 | 3.21 | 67461 | 6.4368468 | CS |
| 260 | 1.03 | 21.6842105263 | 4.75 | 10.6899 | 3.21 | 67461 | 6.4368468 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
